Fraile García L, Aramburu Arnuelos J, López González E, Bellés-Bellés A, Muñoz Santa A, Sánchez Báscones E, Mormeneo Bayo S, Bernet Sánchez A, Prats Sánchez I, Cumplido Portillo A, García González M. Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain.
Rev Esp Quimioter 2024;
37:270-273. [PMID:
38591493 PMCID:
PMC11094637 DOI:
10.37201/req/015.2024]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 03/12/2024] [Indexed: 04/10/2024]
Abstract
OBJECTIVE
Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area.
METHODS
A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG-AziR Assay and AllplexTM MG-MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene.
RESULTS
A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%).
CONCLUSIONS
The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.
Collapse